StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Adjusted SG&A Expense % of Net Revenues by Quarter

Adjusted SG&A Expense % of Net Revenues — Non-GAAP (%) (%)

AbbVie Adjusted SG&A Expense % of Net Revenues: 21.0% in Q2 2026, unchanged from a year earlier.

Latest, Q2 2026
21.0%
Period ended Jun 30, 2026
Change on a year earlier
0.0 pts
21.0% in Q2 2025
History
16 quarters
Since Q3 2022
Sources
16
Documents cited below

Where the Q2 2026 figure comes from

“On a GAAP basis, selling, general and administrative (SG&A) expense was 21.4 percent of net revenues. The adjusted SG&A expense was 21.0 percent of net revenues.”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Earnings Release.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdjusted SG&A Expense % of Net Revenues — Non-GAAP (%) (%)Year on yearSource
Q2 2026Jun 30, 202621.0%0.0 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202622.7%-1.9 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202522.3%-1.3 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202521.6%-1.4 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 202521.0%-1.9 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202524.6%0.0 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202423.6%-1.1 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202423.0%-0.9 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202422.9%-0.3 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 202424.6%+0.2 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202324.7%+3.9 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 202323.9%+3.0 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 202323.2%–Form 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 202324.4%–Form 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202220.8%–Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 202220.9%–Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Breakdown

What makes up adjusted SG&A Expense % of Net Revenues

Cite this data

StockData. (2026). AbbVie Adjusted SG&A Expense % of Net Revenues (%), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/margin-adj-sga

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.